top of page


In this issue of GOLD, we highlight some of the top news stories from the pharmaceutical industry that have come to light over the past few months. The COVID-19 pandemic is still dominating headlines, as vaccines go to trial and research funds are launched, but amid all of this, other partnerships, acquisitions, and appointments are also emerging.

20 April

Novartis reach an agreement with the FDA to sponsor Phase III hydroxychloroquine clinical trials in COVID-19 patients

27 April

ViiV Healthcare announce a £3 million Global HIV and COVID-19 Emergency Response Fund for research into COVID-19 in people living with HIV

04 May

Italian pharmaceutical company Menarini agrees to buy Stemline Therapeutics in a $677 million acquisition

06 May

Gilead announce collaborations with generics firms to fast-track production of remdesivir amid suggestions that the drug may be approved for COVID-19 patients

08 May

AbbVie’s acquisition of Allergan completes, expanding the company’s portfolio in immunology and haematologic oncology

19 May

Moderna announce plans to raise $1.34 billion to fund Phase III trials of a mRNA-based COVID-19 vaccine

21 May

AstraZeneca receive over $1 billion from BARDA to develop, produce, and deliver Oxford University’s COVID-19 vaccine, promising to supply 400 million doses

22 May

Roche’s Tecentriq® is recommended by NICE for treating patients with triple negative breast cancer that has spread across the body

29 May

Sanofi’s former Executive VP of Vaccines, David Loew, is announced as new Ipsen CEO, effective 1st July, replacing David Meek

01 June

FDA grants approval for AstraZeneca’s Brilinta drug for patients with coronary artery disease who are high risk for a first heart attack or stroke

02 June

CSL Behring announce partnership with Seattle Children’s Research Institute, developing stem cell gene therapies for patients with primary immunodeficiency diseases

03 June

The American Thoracic Society announces AstraZeneca’s donation of $500,000 to the organisation’s Crisis Fund for COVID-19 research

Read next

Subscribe to GOLD


Sign up to receive a weekly roundup of our latest articles, interviews and more 

bottom of page